Literature DB >> 1674359

Biochemical and behavioural effects of isamoltane, a beta-adrenoceptor antagonist with affinity for the 5-HT1B receptor of rat brain.

L Rényi1, L G Larsson, S Berg, B E Svensson, G Thorell, S B Ross.   

Abstract

The biochemical and behavioural effects of isamoltane, a beta-adrenoceptor and 5-HT1B receptor antagonist that has higher affinity for 5-HT1B receptors than for 5-HT1A receptors, on 5-HT neurotransmission in the rat brain were examined. In binding experiments isamoltane was found to be about five times more potent as a ligand for the 5-HT1B receptor than for the 5-HT1A receptor (Ki values 21 and 112 nmol/l, respectively). Isamoltane increased the K(+)-evoked overflow of 3H from 3H-5-HT loaded slices of rat occipital cortex at 0.1 mumol/l, consistent with inhibition of the terminal 5-HT autoreceptor. In vivo, isamoltane significantly increased the concentration of 5-hydroxyindoleacetic acid in hypothalamus and hippocampus indicating an increased 5-HT turnover with a maximal effect at 3 mg/kg s.c. A higher dose produced a less pronounced effect. This effect did not seem to be due to the beta-adrenoceptor blocking action of isamoltane since the beta-adrenoceptor antagonists. (-)-alprenolol, betaxolol or ICI 118.551 had no significant effects on 5-HT turnover at 5 mg/kg s.c. Isamoltane at 3 mg/kg s.c. induced the wet-dog shake response which was blocked by the tryptophan hydroxylase inhibitor p-chlorophenylalanine. In contrast, the same response induced by the 5-HT2 receptor agonist quipazine was not blocked by pretreatment with p-chlorophenylalanine. The wet-dog shakes evoked by isamoltane and quipazine were blocked by ritanserin, which indicates that 5-HT2 receptors are involved in their expression. These observations indicate that isamoltane, by inhibiting the terminal 5-HT autoreceptors, increased the synaptic concentration of 5-HT to a level that induced a behavioural response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674359     DOI: 10.1007/bf00180669

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

Review 1.  Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain.

Authors:  D Hoyer; D N Middlemiss
Journal:  Trends Pharmacol Sci       Date:  1989-04       Impact factor: 14.819

2.  Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain.

Authors:  P C Waldmeier; M Williams; P A Baumann; S Bischoff; M A Sills; R F Neale
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

3.  Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol.

Authors:  D Hoyer; G Engel; H O Kalkman
Journal:  Eur J Pharmacol       Date:  1985-11-26       Impact factor: 4.432

4.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

5.  Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites.

Authors:  G Engel; M Göthert; D Hoyer; E Schlicker; K Hillenbrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

6.  Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

7.  Serotonin autoreceptor in rat hippocampus: pharmacological characterization as a subtype of the 5-HT1 receptor.

Authors:  G Maura; E Roccatagliata; M Raiteri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-12       Impact factor: 3.000

8.  Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI.

Authors:  J Arnt; J Hyttel
Journal:  Eur J Pharmacol       Date:  1989-02-14       Impact factor: 4.432

9.  Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine.

Authors:  M E Trulson; B L Jacobs
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

10.  Pharmacological characterization of release-regulating serotonin autoreceptors in rat cerebellum.

Authors:  G Bonanno; G Maura; M Raiteri
Journal:  Eur J Pharmacol       Date:  1986-07-31       Impact factor: 4.432

View more
  4 in total

1.  Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).

Authors:  Simon D Brandt; Pierce V Kavanagh; Brendan Twamley; Folker Westphal; Simon P Elliott; Jason Wallach; Alexander Stratford; Landon M Klein; John D McCorvy; David E Nichols; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2017-07-27       Impact factor: 3.345

2.  Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan.

Authors:  Louis P Vera-Portocarrero; Michael H Ossipov; Tamara King; Frank Porreca
Journal:  Gastroenterology       Date:  2008-07-03       Impact factor: 22.682

Review 3.  N-Pyrrylarylsulfones with High Therapeutic Potential.

Authors:  Valeria Famiglini; Sabrina Castellano; Romano Silvestri
Journal:  Molecules       Date:  2017-03-09       Impact factor: 4.411

4.  Cascade Synthesis of Pyrroles from Nitroarenes with Benign Reductants Using a Heterogeneous Cobalt Catalyst.

Authors:  Pavel Ryabchuk; Thomas Leischner; Carsten Kreyenschulte; Anke Spannenberg; Kathrin Junge; Matthias Beller
Journal:  Angew Chem Int Ed Engl       Date:  2020-08-31       Impact factor: 16.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.